A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Gotham Asset Management, LLC holds 158,155 shares of GANX stock, worth $300,494. This represents 0.0% of its overall portfolio holdings.

Number of Shares
158,155
Previous 334,592 52.73%
Holding current value
$300,494
Previous $595,000 45.88%
% of portfolio
0.0%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$1.54 - $2.92 $271,712 - $515,196
-176,437 Reduced 52.73%
158,155 $322,000
Q3 2024

Nov 14, 2024

BUY
$0.94 - $1.99 $314,516 - $665,838
334,592 New
334,592 $595,000

Others Institutions Holding GANX

About Gain Therapeutics, Inc.


  • Ticker GANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,883,400
  • Market Cap $22.6M
  • Description
  • Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...
More about GANX
Track Joel Greenblatt's Portfolio

Track Joel Greenblatt Portfolio

Follow Joel Greenblatt (Gotham Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.